# PHARMO Institute Seroquel Safety Study

> **NCT01342120** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 18325 (actual)

## Conditions studied

- Schizophrenia
- Major Depressive Disorder
- Bipolar Disorder
- Generalized Anxiety Disorder

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01342120
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 18325 (ACTUAL)
- **Last updated:** 2011-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342120, "PHARMO Institute Seroquel Safety Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01342120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*